The BC trial recently announced will be both for cancer efficacy and cardioprotection. It's not only for cardioprotection.
Cardioprotection is a much easier sell than FTO inhibition because all oncologists are aware of the cardiotoxicity problem, whereas FTO's role is relatively new and requires some education of oncologists.
RAC says that the new trial is in response to doctors' requests already received after the recent preclinical results.
General Comments / Chat, page-4811
-
- There are more pages in this discussion • 6,466 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |